Reduction of immune activation with chloroquine therapy during chronic HIV infection.
Increased levels of activated T cells are a hallmark of the chronic stage of human immunodeficiency virus (HIV) infection and are highly correlated with HIV disease progression. We evaluated chloroquine (CQ) as a potential therapy to reduce immune activation during HIV infection. We found that the frequency of CD38(+) HLA-DR(+) CD8 T cells, as well as Ki-67 expression in CD8 and CD4 T cells, was significantly reduced during CQ treatment. Our data indicate that treatment with CQ reduces systemic T-cell immune activation and, thus, that its use may be beneficial for certain groups of HIV-infected individuals.
Murray
Shannon M
SM
Human Immunology Section, NIH Vaccine Research Center, Bethesda, MD 20892-3005, USA.
Down
Carrie M
CM
Boulware
David R
DR
Stauffer
William M
WM
Cavert
Winston P
WP
Schacker
Timothy W
TW
Brenchley
Jason M
JM
Douek
Daniel C
DC
D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D002738:Chloroquine / Q000008:administration & dosage*; D002908:Chronic Disease / Q000628:therapy; D015536:Down-Regulation / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D019394:Ki-67 Antigen / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects
D019394:Ki-67 Antigen; D002738:Chloroquine